Anakinra is a commonly used drug for the treatment of inflammatory diseases such as rheumatoid arthritis. It is administered by injection, and the common dosage form is injection. The dosage of Anakinra needs to be determined according to the patient's specific situation and severity, and is generally adjusted individually by the doctor based on the patient's weight, age, condition and other factors. During use, it is necessary to strictly follow the doctor's instructions and inject on time and in the right amount. During the treatment process, patients should have regular follow-up visits and cooperate with the doctor's monitoring and adjustments to achieve the best therapeutic effect.

Dosage and Usage of Anakinra

1. Active Rheumatoid Arthritis

The recommended dose of Anakinra for the treatment of patients with rheumatoid arthritis is 100 mg/day, subcutaneously injected daily. Higher doses do not lead to higher reactions and should be administered at approximately the same time each day.

2. Cryoprotein-Associated Periodic Syndrome (CAPS)

For patients with multisystem inflammatory disease (NOMID), the recommended starting dose of Anakinra is 1-2 mg/kg. To control active inflammation, the dose can be individually adjusted to a maximum of 8 mg/kg per day, and the dose can be adjusted in increments of 0.5-1 mg/kg.

It is generally recommended to dosing once a day, but it can also be divided into 2 doses per day. Each syringe is for one use only, and a new syringe must be used for each dose. The unused portion should be discarded after each dose.

3. Interleukin-1 receptor antagonist deficiency (DIRA)

For patients with interleukin-1 receptor antagonist (DIRA) deficiency, the recommended starting dose of Anakinra is 1-2 mg/kg. To control active inflammation, the dose can be individually adjusted to a maximum of 8 mg/kg per day, and the dose can be adjusted in increments of 0.5-1 mg/kg.

Each syringe is for one use only, and a new syringe must be used for each dose. The unused portion should be discarded after each dose.

4. Renal Impairment

For patients with severe renal impairment or end-stage renal disease (creatinine clearance <30 mL/min estimated by serum creatinine level), physicians should consider administering Anakinra at the prescribed dose every other day.

5. Administration

Healthcare providers should provide patients or caregivers with the correct instructions for use. Anakinra should not be administered to patients or caregivers until they fully understand the procedure and are able to properly inject Anakinra. The prescribed dose of Anakinra should be injected according to the instructions for use, and any unused portion should be discarded. After injecting Anakinra, the syringe and any remaining drug must be disposed of according to the correct procedures. For detailed instructions on handling and injecting Anakinra, refer to the "Patient Information" insert.

Do not use Anakinra after the expiration date shown on the carton. Visually inspect the solution for particulate matter and discoloration before administration. The solution may contain trace amounts of small, translucent to white, amorphous protein particles. The prefilled syringe should not be used if the solution is discolored or cloudy, or if foreign particulate matter is present. Do not use a syringe if an excessive number of translucent to white amorphous particles are present in that syringe.